Analysis of growth in branded medicines: 2013 to 2014
Examines factors influencing the 5.19% growth in branded medicines under the Pharmaceutical Price Regulation Scheme (PPRS) in 2013 to 2014.
Documents
Details
In 2013 to 2014, the PPRS growth rate in branded medicines was 5.19% (figure applied at the time the analysis was carried out).
The document examines the factors that have influenced that growth. These include specific therapy areas, manufacturers and products. IMS Health data, which provides product level data across the specified period, has been used to compare the growth in branded medicines.
PPRS data and IMS Health data are not directly comparable due to differences in definitions and price bases - however, the IMS Health data gives a good indication of the reasons behind the growth. This analysis has been shared and agreed with the Association of the British Pharmaceutical Industry (ABPI).
The publication of this data is conditional on the fact that analysis of IMS Health data is independently arrived at by the Department of Health on the basis of the data provided and other information, and that IMS Health is not responsible for any reliance by recipients of the data or any analysis of it.